Robert E. Landry - 31 Mar 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
31 Mar 2022
Net transactions value
-$450,357
Form type
4
Filing time
01 Apr 2022, 16:07:02 UTC
Previous filing
30 Mar 2022
Next filing
11 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $599,490 +1,500 +5.2% $399.66 30,244 31 Mar 2022 Direct F1
transaction REGN Common Stock Tax liability $829,972 -1,184 -3.9% $700.99 29,060 31 Mar 2022 Direct F1
transaction REGN Common Stock Sale $209,346 -301 -1% $695.50 28,759 01 Apr 2022 Direct F1
transaction REGN Common Stock Sale $10,530 -15 -0.05% $701.98 28,744 01 Apr 2022 Direct F1
holding REGN Common Stock 229 31 Mar 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,500 -30% $0.000000 3,500 31 Mar 2022 Common Stock 1,500 $399.66 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.